$
15.130
-0.25(-1.625%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.500
Open
15.370
VWAP
15.02
Vol
193.50K
Mkt Cap
546.84M
Low
14.720
Amount
2.91M
EV/EBITDA(TTM)
--
Total Shares
36.14M
EV
383.76M
EV/OCF(TTM)
--
P/S(TTM)
7.39
CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
Show More
6 Analyst Rating
up Image
107.53% Upside
Wall Street analysts forecast CBLL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBLL is 31.40 USD with a low forecast of 26.00 USD and a high forecast of 36.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
107.53% Upside
Current: 15.130
sliders
Low
26.00
Averages
31.40
High
36.00
BTIG
Marie Thibault
initiated
$30
2025-06-24
Reason
Ladenburg Thalmann
Jeff Cohen
Strong Buy
Initiates
$32
2025-04-04
Reason
Ladenburg initiated coverage of Ceribell with a Buy rating and $32 price target. The company has a first-mover advantage in scaling rapid electroencephalography technology for acute neurological care, the analyst tells investors in a research note.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$33
2025-02-26
Reason
TD Cowen
Joshua Jennings
Strong Buy
Maintains
$31 → $36
2024-12-09
Reason
TD Cowen analyst Joshua Jennings raised the firm's price target on Ceribell to $36 from $31 and keeps a Buy rating on the shares. The firm said its target increase reflects a slightly higher EV/sales multiple of 10.5 applied to their unchanged 2026 estimate and an updated share count.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$31 → $33
2024-12-09
Reason
Canaccord raised the firm's price target on Ceribell to $33 from $31 and keeps a Buy rating on the shares. Canaccord said they are bullish on the Med-Tech sector heading into 2025 as they expect investor interest to increase given smid-cap valuations continue to remain depressed while M&A has picked up and the IPO market seems to have opened. They highlight how AI is changing the space and are seeing continued interest in value-based care in the US, and believe that med-tech is well positioned to help drive the trend for improving patient outcomes while also reducing overall costs.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$30 → $31
2024-11-13
Reason
Canaccord raised the firm's price target on Ceribell to $31 from $30 and keeps a Buy rating on the shares. The firm said its first conference call as a public company was fairly straightforward, with the only new incremental news since our initiation was the company's recent authority to operate from the US Department of Veterans Affairs, which unlocks the VA and being able to connect to their networks for Ceribell.

Valuation Metrics

The current forward P/E ratio for CeriBell Inc (CBLL.O) is -9.81, compared to its 5-year average forward P/E of -13.78. For a more detailed relative valuation and DCF analysis to assess CeriBell Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.78
Current PE
-9.81
Overvalued PE
-7.87
Undervalued PE
-19.69

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-15.04
Current EV/EBITDA
-7.04
Overvalued EV/EBITDA
-5.96
Undervalued EV/EBITDA
-24.11

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
8.79
Current PS
6.24
Overvalued PS
12.23
Undervalued PS
5.35

Financials

Annual
Quarterly
FY2025Q1
YoY :
+42.30%
20.49M
Total Revenue
FY2025Q1
YoY :
+68.07%
-14.21M
Operating Profit
FY2025Q1
-12.78M
Net Income after Tax
FY2025Q1
YoY :
+44.00%
-0.36
EPS - Diluted
FY2025Q1
YoY :
+20.66%
-11.68M
Free Cash Flow
FY2025Q1
YoY :
+2.53%
87.88
Gross Profit Margin - %
FY2025Q1
-54.02
FCF Margin - %
FY2025Q1
YoY :
+5.37%
-62.35
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.0M
USD
6
3-6
Months
376.9K
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
10.5M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
551.2K
Volume
Months
6-9
8
6.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CBLL News & Events

Events Timeline

2025-07-07 (ET)
2025-07-07
16:46:30
Ceribell files complaints against Natus Medical, alleges patent infringement
select
2025-05-08 (ET)
2025-05-08
17:21:11
Ceribell raises FY25 revenue view to $83M-$87M from $81M-$85M, consensus $83.71M
select
2025-05-08
17:19:57
Ceribell reports Q1 EPS (36c), consensus (46c)
select
Sign Up For More Events

News

7.0
07-07Newsfilter
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
7.0
07-07SeekingAlpha
Ceribell sues Natus Medical for patent infringement
3.5
06-20PRnewswire
AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape
Sign Up For More News

FAQ

arrow icon

What is CeriBell Inc (CBLL) stock price today?

The current price of CBLL is 15.13 USD — it has decreased -1.63 % in the last trading day.

arrow icon

What is CeriBell Inc (CBLL)'s business?

arrow icon

What is the price predicton of CBLL Stock?

arrow icon

What is CeriBell Inc (CBLL)'s revenue for the last quarter?

arrow icon

What is CeriBell Inc (CBLL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for CeriBell Inc (CBLL)'s fundamentals?

arrow icon

How many employees does CeriBell Inc (CBLL). have?

arrow icon

What is CeriBell Inc (CBLL) market cap?